Who Paid My Doc
George Stouffer
Cardiovascular Disease Chapel Hill, ND Medical Doctor
NPI 1003994286 CMS profile 272579
101 Manning Dr, Chapel Hill, ND 27599
General payments
$3,646
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$259,143
Through program year 2025, George Stouffer of Chapel Hill, ND is reported in the CMS Open Payments database as having received $3,646 across 29 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $259,143 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 62nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $270 | 4 | |
| 2024 | General | $429 | 5 | |
| 2023 | General | $377 | 7 | |
| 2022 | General | $137 | 5 | |
| 2021 | General | $1,068 | 2 | |
| 2020 | General | $154 | 2 | |
| 2019 | General | $1,211 | 4 |
Beside peers
- George Stouffer
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to George Stouffer were reported at $270. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | George Stouffer | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,211 | $450 | $127–$1,392 | $163 |
| 2020 | $154 | $242 | $77–$751 | $114 |
| 2021 | $1,068 | $335 | $101–$1,037 | $132 |
| 2022 | $137 | $395 | $121–$1,211 | $149 |
| 2023 | $377 | $443 | $136–$1,283 | $160 |
| 2024 | $429 | $450 | $136–$1,323 | $164 |
| 2025 | $270 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
712
Drug cost
$109,499
Branded share of claims
28.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Repatha Sureclick Evolocumab | Brand | 39 | $47,951 | |
| Eliquis Apixaban | Brand | 18 | $22,700 | |
| Farxiga Dapagliflozin Propanediol | Brand | 16 | $13,371 | |
| Xarelto Rivaroxaban | Brand | 11 | $12,356 | |
| Nexletol Bempedoic Acid | Brand | 12 | $4,812 | |
| Prasugrel Hcl | Generic | 40 | $2,407 | |
| Atorvastatin Calcium | Generic | 81 | $894 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 67 | $885 | |
| Metoprolol Succinate | Generic | 66 | $654 | |
| Verapamil Er Verapamil Hcl | Brand | 14 | $645 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$53,072
Medicare patients
208
Services billed
524
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 73% | |
| Arthritis | 50% | |
| Diabetes | 40% | |
| Chronic kidney disease | 35% | |
| Heart failure | 33% | |
| Atrial fibrillation | 29% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in North Dakota
Noah Chelliah
Cardiovascular Disease · Grand Forks, ND
Beng Loong Isaac Tea
Cardiovascular Disease · Minot, ND
Hussain Basrawala
Cardiovascular Disease · Grand Forks, ND
Thomas Haldis
Cardiovascular Disease · Fargo, ND
Matthew Glogoza
Cardiovascular Disease · Fargo, ND
Mikhail Kirnus
Cardiovascular Disease · Grand Forks, ND
Related records
Cardiovascular Disease in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.